|
US5846547A
(en)
*
|
1996-01-22 |
1998-12-08 |
Regents Of The University Of Minnesota |
Streptococcal C5a peptidase vaccine
|
|
US6355255B1
(en)
|
1998-12-07 |
2002-03-12 |
Regents Of The University Of Minnesota |
Streptococcal C5a peptidase vaccine
|
|
US6676943B1
(en)
|
1997-04-24 |
2004-01-13 |
Regents Of The University Of Minnesota |
Human complement C3-degrading protein from Streptococcus pneumoniae
|
|
US6444787B1
(en)
*
|
1997-12-31 |
2002-09-03 |
Research Development Institute, Inc. |
Method of isolating a peptide which immunologically mimics microbial carbohydrates including group B streptococcal carbohydrates and the use thereof in a vaccine
|
|
EP1115875A1
(en)
*
|
1998-09-24 |
2001-07-18 |
Regents Of The University Of Minnesota |
Human complement c3-degrading polypeptide from streptococcus pneumoniae
|
|
US7256265B2
(en)
*
|
1999-12-03 |
2007-08-14 |
Regents Of The University Of Minnesota |
Streptococcal C5a peptidase vaccine
|
|
AU2004226909B2
(en)
*
|
2000-10-27 |
2008-02-07 |
J. Craig Venter Institute, Inc. |
Nucleic acids and proteins from streptococcus groups A & B
|
|
US7939087B2
(en)
|
2000-10-27 |
2011-05-10 |
Novartis Vaccines And Diagnostics, Inc. |
Nucleic acids and proteins from Streptococcus groups A & B
|
|
GB2370770B
(en)
*
|
2001-01-03 |
2005-06-01 |
Simon Connolly |
Uses of Streptococcus Vaccines
|
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
|
WO2004018646A2
(en)
*
|
2002-08-26 |
2004-03-04 |
Chiron Corporation |
Conserved and specific streptococcal genomes
|
|
US7785608B2
(en)
*
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
|
US7301554B2
(en)
*
|
2002-09-20 |
2007-11-27 |
Ricoh Company, Ltd. |
Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
|
|
US7709009B2
(en)
*
|
2003-07-31 |
2010-05-04 |
Novartis Vaccines And Diagnostics, Srl |
Immunogenic compositions for streptococcus pyogenes
|
|
US8945589B2
(en)
*
|
2003-09-15 |
2015-02-03 |
Novartis Vaccines And Diagnostics, Srl |
Immunogenic compositions for Streptococcus agalactiae
|
|
WO2006078318A2
(en)
|
2004-07-29 |
2006-07-27 |
Novartis Vaccines And Diagnostics Inc. |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
|
EP1807446A2
(en)
*
|
2004-10-08 |
2007-07-18 |
Novartis Vaccines and Diagnostics, Inc. |
Immunogenic and therapeutic compositions for streptococcus pyogenes
|
|
TW200806315A
(en)
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
|
DK2054431T3
(da)
*
|
2006-06-09 |
2012-01-02 |
Novartis Ag |
Konformere af bakterielle adhæsiner
|
|
US7364291B2
(en)
*
|
2006-06-29 |
2008-04-29 |
Johnson & Johnson Vision Care, Inc. |
Contact lenses with light blocking rings
|
|
AU2007348285A1
(en)
*
|
2006-10-30 |
2008-09-12 |
Novartis Ag |
Immunogenic and therapeutic compositions for streptococcus pyogenes
|
|
US20080311129A1
(en)
*
|
2006-11-02 |
2008-12-18 |
Camas Incorporated |
Adherence inhibitor directed to and method of making and using
|
|
AR064642A1
(es)
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
|
|
HU227970B1
(en)
|
2007-07-10 |
2012-07-30 |
Egis Gyogyszergyar Nyrt |
Pharmaceutical compositions containing silicones of high volatility
|
|
US8287885B2
(en)
|
2007-09-12 |
2012-10-16 |
Novartis Ag |
GAS57 mutant antigens and GAS57 antibodies
|
|
NZ586430A
(en)
|
2007-12-21 |
2012-09-28 |
Novartis Ag |
Mutant forms of streptolysin o (slo)
|
|
AU2009313615B2
(en)
|
2008-11-05 |
2012-11-29 |
Regents Of The University Of Minnesota |
Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (BHS) disease
|
|
EP3626263A1
(en)
|
2010-06-04 |
2020-03-25 |
Wyeth LLC |
Vaccine formulations
|
|
CA2808975C
(en)
|
2010-08-23 |
2018-10-30 |
Wyeth Llc |
Stable formulations of neisseria meningitidis rlp2086 antigens
|
|
KR101584871B1
(ko)
|
2010-09-10 |
2016-01-22 |
와이어쓰 엘엘씨 |
네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
|
|
ITMI20111182A1
(it)
|
2011-06-28 |
2012-12-29 |
Canio Buonavoglia |
Vaccino per coronavirus canino
|
|
US9078842B2
(en)
*
|
2011-10-26 |
2015-07-14 |
Wisconsin Alumni Research Foundation |
Peptide for reducing the phosphate requirement and excretion from farm animals
|
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
|
CA2865745C
(en)
|
2012-03-09 |
2018-01-09 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
|
CA2903716C
(en)
|
2013-03-08 |
2019-04-09 |
Pfizer Inc. |
Immunogenic fusion polypeptides
|
|
RU2662968C2
(ru)
|
2013-09-08 |
2018-07-31 |
Пфайзер Инк. |
Иммуногенная композиция против neisseria meningitidis (варианты)
|
|
EP2886140A1
(en)
*
|
2013-12-17 |
2015-06-24 |
University of Limerick |
An apparatus for the extracorporeal treatment of blood
|
|
US9107906B1
(en)
|
2014-10-28 |
2015-08-18 |
Adma Biologics, Inc. |
Compositions and methods for the treatment of immunodeficiency
|
|
KR20190049940A
(ko)
|
2015-02-19 |
2019-05-09 |
화이자 인코포레이티드 |
나이세리아 메닌지티디스 조성물 및 그의 방법
|
|
US10544197B2
(en)
*
|
2016-08-12 |
2020-01-28 |
Wisconsin Alumni Research Foundation |
FGF-23 epitope peptide for improving resistance to breakage and eggshell strength
|
|
SG11201906519RA
(en)
|
2017-01-31 |
2019-08-27 |
Pfizer |
Neisseria meningitidis compositions and methods thereof
|
|
US10259865B2
(en)
|
2017-03-15 |
2019-04-16 |
Adma Biologics, Inc. |
Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
|
|
CA3155669A1
(en)
|
2019-09-27 |
2021-04-01 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
|
MX2023004912A
(es)
|
2020-10-27 |
2023-05-16 |
Pfizer |
Composiciones de escherichia coli y metodos de las mismas.
|
|
US12357681B2
(en)
|
2020-12-23 |
2025-07-15 |
Pfizer Inc. |
E. coli FimH mutants and uses thereof
|
|
CA3221075A1
(en)
|
2021-05-28 |
2022-12-01 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
JP7714690B2
(ja)
|
2021-05-28 |
2025-07-29 |
ファイザー・インク |
コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
|
|
JP2025508749A
(ja)
|
2022-01-13 |
2025-04-10 |
ファイザー・インク |
コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
|
|
WO2024110827A1
(en)
|
2022-11-21 |
2024-05-30 |
Pfizer Inc. |
Methods for preparing conjugated capsular saccharide antigens and uses thereof
|
|
EP4622665A2
(en)
|
2022-11-22 |
2025-10-01 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
WO2024166008A1
(en)
|
2023-02-10 |
2024-08-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
AU2024246082A1
(en)
|
2023-03-30 |
2025-10-16 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
PE20252779A1
(es)
|
2023-04-14 |
2025-12-22 |
Pfizer |
Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos
|
|
WO2024224266A1
(en)
|
2023-04-24 |
2024-10-31 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
TW202527906A
(zh)
|
2023-09-14 |
2025-07-16 |
美商輝瑞股份有限公司 |
包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途
|
|
WO2025133971A1
(en)
|
2023-12-23 |
2025-06-26 |
Pfizer Inc. |
Improved methods for producing bacterial capsular saccharide glycoconjugates
|
|
WO2025186705A2
(en)
|
2024-03-06 |
2025-09-12 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
TW202602467A
(zh)
|
2024-03-11 |
2026-01-16 |
美商輝瑞股份有限公司 |
包含經共軛之大腸桿菌糖的免疫原性組成物及其用途
|
|
WO2025219904A1
(en)
|
2024-04-19 |
2025-10-23 |
Pfizer Inc. |
Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
|
|
WO2025219908A2
(en)
|
2024-04-19 |
2025-10-23 |
Pfizer Inc. |
Media and fermentation methods for polysaccharide production in bacterial cell culture
|